Morgan Stanley Maintains Equal-Weight on TransMedics Gr, Raises Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $104 to $145.
July 15, 2024 | 4:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley analyst Patrick Wood maintains an Equal-Weight rating on TransMedics Group and raises the price target from $104 to $145.
The raised price target from $104 to $145 by a reputable analyst at Morgan Stanley is likely to positively impact the stock price of TransMedics Group in the short term. The Equal-Weight rating suggests a neutral stance, but the significant increase in the price target indicates a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100